Our lead program, JSP191, is a first-in-class monoclonal antibody in development as a conditioning agent for hematopoietic cell transplant. The initial indication is severe combined immunodeficiency (SCID), for which we are currently conducting a Phase 1 study. We also are evaluating JSP191 in a Phase 1/2 study in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Future indications include sickle cell disease, Fanconi anemia, autoimmune disorders and gene therapy. We plan to expand our pipeline to other novel therapies for immune modulation, graft engineering and cell and gene therapies.

Information about the SCID and MDS/AML trials can be found at clinicaltrials.gov. Click here for the SCID detail and here for the MDS/AML detail.